• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

低分子量肝素与持续输注普通肝素用于机械人工瓣膜植入术后启动抗凝治疗的疗效、安全性及成本比较。

Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation.

作者信息

Fanikos John, Tsilimingras Kanella, Kucher Nils, Rosen Allison B, Hieblinger Melissa D, Goldhaber Samuel Z

机构信息

Cardiovascular Division, the Department of Pharmacy, and Center for Clinical Excellence, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

出版信息

Am J Cardiol. 2004 Jan 15;93(2):247-50. doi: 10.1016/j.amjcard.2003.09.054.

DOI:10.1016/j.amjcard.2003.09.054
PMID:14715362
Abstract

We compared the efficacy, safety, and impact on postoperative hospital length of stay and inpatient hospital costs of low-molecular-weight heparin with that of unfractionated heparin as a "bridge" to achieving therapeutic levels of anticoagulation with warfarin in patients with newly implanted prosthetic heart valves. The patients who received low-molecular-weight heparin had a shorter length of stay and decreased postoperative costs compared with the control subjects receiving unfractionated heparin.

摘要

我们比较了低分子量肝素与普通肝素在新植入人工心脏瓣膜患者中作为“桥梁”以达到华法林治疗性抗凝水平的疗效、安全性以及对术后住院时间和住院费用的影响。与接受普通肝素的对照组相比，接受低分子量肝素的患者住院时间更短，术后费用降低。

相似文献

1
Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation.低分子量肝素与持续输注普通肝素用于机械人工瓣膜植入术后启动抗凝治疗的疗效、安全性及成本比较。
Am J Cardiol. 2004 Jan 15;93(2):247-50. doi: 10.1016/j.amjcard.2003.09.054.
2
Low-molecular-weight heparin for prosthetic heart valves: treatment failure.低分子量肝素用于人工心脏瓣膜：治疗失败
Ann Thorac Surg. 2000 Jan;69(1):264-5; discussion 265-6. doi: 10.1016/s0003-4975(99)00874-7.
3
Early postoperative anticoagulation after mechanical valve replacement: a systematic review.机械瓣膜置换术后早期抗凝治疗：一项系统评价。
Ann Thorac Surg. 2006 Feb;81(2):770-81. doi: 10.1016/j.athoracsur.2005.07.023.
4
Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.住院患者静脉血栓栓塞症治疗选择相关的经济和使用结果
Value Health. 2005 May-Jun;8(3):191-200. doi: 10.1111/j.1524-4733.2005.04026.x.
5
Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery.依诺肝素与未分级肝素用于行非心脏手术的机械性心脏瓣膜置换患者围术期抗凝治疗。
Medicina (Kaunas). 2022 Aug 18;58(8):1119. doi: 10.3390/medicina58081119.
6
Anticoagulant management of pregnancy following heart valve replacement in the United Kingdom, 1986-2002.1986 - 2002年英国心脏瓣膜置换术后妊娠的抗凝管理
J Heart Valve Dis. 2008 Sep;17(5):526-32.
7
The use of enoxaparin as bridge to therapeutic INR after LVAD implantation.在 LVAD 植入后使用依诺肝素作为桥接至治疗性 INR。
J Cardiothorac Surg. 2020 Nov 14;15(1):329. doi: 10.1186/s13019-020-01373-y.
8
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Haemostasis. 1996 Oct;26 Suppl 4:189-98. doi: 10.1159/000217298.
9
Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation.低分子量肝素预防妊娠期人工二尖瓣血栓形成失败：病例报告及抗凝治疗选择综述
J Heart Valve Dis. 2002 Sep;11(5):745-50.
10
Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.血管外科术后抗凝治疗：第1部分。普通肝素与低分子肝素临床结局的回顾性比较。
J Vasc Nurs. 2001 Jun;19(2):42-9; quiz 50-1. doi: 10.1067/mvn.2001.115784.

引用本文的文献

1
Practice Patterns of Antithrombotic Therapy during the Early Postoperative Course of Cardiac Surgery.心脏手术后早期抗血栓治疗的实践模式
J Clin Med. 2023 Mar 3;12(5):2029. doi: 10.3390/jcm12052029.
2
Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.比较机械二尖瓣置换术后抗凝治疗中起始剂量 3 毫克和 5 毫克的华法林：一项前瞻性随机试验。
Clin Drug Investig. 2022 Apr;42(4):309-318. doi: 10.1007/s40261-022-01137-7. Epub 2022 Mar 10.
3
Coronavirus disease 2019 (COVID-19) and prosthetic heart valve: An additional coagulative challenge.
2019冠状病毒病（COVID-19）与人工心脏瓣膜：又一个凝血方面的挑战。
World J Emerg Med. 2020;11(4):258-259. doi: 10.5847/wjem.j.1920-8642.2020.04.009.
4
Comparison of different bridging anticoagulation therapies used after mechanical heart valve replacement in Chinese patients - a prospective cohort study.中国患者机械心脏瓣膜置换术后不同桥接抗凝治疗的比较——一项前瞻性队列研究
J Cardiothorac Surg. 2020 Feb 24;15(1):40. doi: 10.1186/s13019-020-1084-7.
5
Benefits may not outweigh risks of low molecular weight heparin (LMWH) in early postoperative thromboprophylaxis following minimally invasive cardiac surgery: a propensity score-matched analysis.在微创心脏手术后早期进行血栓预防时，低分子量肝素（LMWH）的获益可能并不超过风险：一项倾向评分匹配分析。
J Thorac Dis. 2019 Dec;11(12):5266-5273. doi: 10.21037/jtd.2019.11.56.
6
A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin.低分子量肝素与肝素之间桥接抗凝的荟萃分析。
Medicine (Baltimore). 2020 Jan;99(3):e18729. doi: 10.1097/MD.0000000000018729.
7
Low molecular weight heparin in surgical valve procedures: When and how much for an optimal prophylaxis?外科瓣膜手术中低分子量肝素的应用：何时使用及使用多少剂量可实现最佳预防效果？
Cardiol J. 2020;27(5):548-557. doi: 10.5603/CJ.a2018.0146. Epub 2018 Nov 28.
8
Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.机械心脏瓣膜患者围手术期使用低分子量肝素进行桥接治疗的策略与结果
J Thromb Thrombolysis. 2015 Nov;40(4):430-6. doi: 10.1007/s11239-015-1216-4.
9
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience.专门的儿科心脏抗凝计划的效用：波士顿儿童医院的经验
Pediatr Cardiol. 2015 Apr;36(4):842-50. doi: 10.1007/s00246-014-1089-x. Epub 2015 Jan 9.
10
Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.瓣膜疾病的抗栓和溶栓治疗：抗栓治疗与血栓预防，第 9 版：美国胸科医师学院循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305.